Allows BioPharmX to Leverage UPM’s Outsourced Manufacturing for
Anticipated High-Volume Consumer Product

BRISTOL, Tenn., (December 10, 2014 /PRNewswire/)
− UPM Pharmaceuticals, a division of Gregory Pharmaceutical Holdings, Inc., has reached an agreement with BioPharmX, Inc. (OTCQB: BPMX) to commercially manufacture solid dose iodine supplement tablets for the consumer products sector. The tablets will be manufactured at UPM’s 475,000 square-foot manufacturing facility in Bristol, Tennessee, under a commercial supply agreement. Terms of the agreement were not disclosed.

Dr. John M. Gregory, Chairman and CEO of Gregory Pharmaceuticals, said, “UPM’s new large-scale manufacturing facility and capabilities for solid dose processing is an ideal setting for BioPharmX, which has a focus on patented products in fast growing markets.”

Anja Krammer, President of BioPharmx, commented, “BioPharmX is impressed with UPM’s customer focus and agile responsiveness toward supporting outsourced manufacturing needs, both critical elements to BioPharmX’s anticipated growth in the over-the-counter and dietary supplements industry. We are excited about our planned product portfolio and the near-term launch of our innovative iodine-based supplement, where UPM will be an essential partner in meeting what we believe will eventually be high-volume manufacturing requirements for BioPharmX,” continued Krammer.

About UPM Pharmaceuticals

UPM Pharmaceuticals, Inc. a wholly owned division of Gregory Pharmaceutical Holdings, Inc., is an independent drug development and contract manufacturer serving the pharmaceutical and biotechnology industries. We provide high-quality drug development services including formulation development, cGMP clinical and commercial manufacturing, analytical methods development and stability testing. UPM’s clients enjoy service that is customized and fast with total quality management characteristics of a customer-focused business. Our history includes successful collaborative interactions with small virtual and large billion-dollar companies providing customized product development services and solutions. UPM focuses on drug development for dosages with oral routes of administration, in solid dosage forms such as capsules and tablets, and semi-solid creams and ointments. Our 475,000 square-foot commercial manufacturing facility based in Bristol, Tennessee allows us to serve our clients’ needs from early stage development to large-scale commercial production.

About BioPharmX Corporation

BioPharmX Corporation (OTCQB: BPMX) is a Silicon Valley-based biotechnology company, which seeks to provide innovative products through unique, proprietary platform technologies for pharmaceutical, over-the-counter (“OTC”), and dietary supplement applications in the fast-growing health and wellness markets, including women’s health, dermatology, and otolaryngology (ears, nose & throat). To learn more about BioPharmx, visit www.biopharmx.com.

Forward-Looking Statements

Statements in this news release relating to the business of BioPharmX, which are not historical facts, are “forward-looking statements”. These forward-looking statements may be identified by words such as “expect,” “anticipate,” “believe,” or similar expressions that are intended to identify such forward-looking statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement and the risks and other factors detailed in the company’s filings with the Securities and Exchange Commission (SEC). Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

BioPharmX, the BioPharmX logo and “Biodelivery that makes a difference” are registered trademarks of BioPharmX Corporation


Jay Tebeau, Director, Public Relations
P: 423-989-7070

Nina Brauer, Marketing Communications Manager, BioPharmX
P: 650-889-5030


Add Comment